Alejandro G. Á.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase 2 Evaluation of Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
- Phase III Randomized Double-Blind Study of Rilvegostomig Plus Chemotherapy in Adjuvant Treatment of Resected Biliary Tract Adenocarcinoma
- A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)
Data & Insights
Has run more than one trial at 27 of 92 partner sites.
Specializations
Thoracic Oncology
Clinical research activity is centered on non-small cell lung cancer, small cell lung cancer, and other advanced thoracic malignancies, with interest in both unresectable and metastatic disease. The portfolio also includes biomarker-defined lung cancer populations and treatment-resistant settings.
- Non-small cell lung cancer
- Small cell lung cancer
- Metastatic thoracic tumors
- Biomarker-selected lung cancer
Work in this area reflects involvement in targeted and immunotherapy-based strategies for lung cancer care.
Breast and Gynecologic Cancer
The investigator is active in breast cancer research, including HER2-positive, HER2-negative, and triple-negative breast cancer, as well as ovarian cancer, endometrial cancer, and cervical cancer. This includes advanced, recurrent, and metastatic solid tumor settings.
- HER2-positive breast cancer
- Triple-negative breast cancer
- Ovarian cancer
- Endometrial cancer
These interests align with ongoing evaluation of precision-driven and combination treatment approaches in women’s cancers.
Hematologic Malignancies
Research involvement extends to acute myeloid leukemia, myelodysplastic syndromes, multiple myeloma, and a broad range of B-cell lymphomas, including relapsed or refractory disease. The portfolio also spans acute lymphoblastic leukemia and other aggressive lymphoid cancers.
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Multiple myeloma
- B-cell lymphomas
There is a clear therapeutic focus on refractory hematologic disease and novel targeted or immune-based treatment options.
Genitourinary and Renal Tumors
The investigator contributes to studies in renal cell carcinoma, urothelial carcinoma, and prostate cancer, including metastatic and high-risk localized disease. Interest also covers bladder cancer and upper urinary tract malignancies.
- Renal cell carcinoma
- Urothelial carcinoma
- Prostate cancer
- Bladder cancer
This area includes evaluation of systemic therapies for advanced genitourinary cancers and recurrence prevention after local treatment.
Targeted and Immune-Mediated Therapy Across Solid Tumors
Additional research activity spans molecularly defined solid tumors, including colorectal cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, and head and neck squamous cell carcinoma. The portfolio also includes selected rare tumors and advanced malignancies with specific genomic alterations.
- Colorectal cancer
- Pancreatic cancer
- Gastric cancer
- Head and neck squamous cell carcinoma
These studies support therapeutic innovation in precision oncology and immuno-oncology for difficult-to-treat solid tumors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.